CORD-19:16a812de72963ceda960a168236e8dbe91832d45 / 40080-40349 JSONTXT

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T200","span":{"begin":0,"end":269},"obj":"Sentence"}],"text":"When antibodies to myelin oligodendrocyte glycoprotein (MOG) are injected after the induction of EAE, the severity of the disease is dramatically increased and large demyelinating lesions develop (Genain et al., 1995; Linington et al., 1992; Schluesener et al., 1987) ."}

{"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T200","span":{"begin":0,"end":269},"obj":"Sentence"},{"id":"TextSentencer_T200","span":{"begin":0,"end":269},"obj":"Sentence"},{"id":"T7124","span":{"begin":0,"end":269},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"When antibodies to myelin oligodendrocyte glycoprotein (MOG) are injected after the induction of EAE, the severity of the disease is dramatically increased and large demyelinating lesions develop (Genain et al., 1995; Linington et al., 1992; Schluesener et al., 1987) ."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T151","span":{"begin":97,"end":100},"obj":"Disease"}],"attributes":[{"id":"A151","pred":"mondo_id","subj":"T151","obj":"http://purl.obolibrary.org/obo/MONDO_0005156"}],"text":"When antibodies to myelin oligodendrocyte glycoprotein (MOG) are injected after the induction of EAE, the severity of the disease is dramatically increased and large demyelinating lesions develop (Genain et al., 1995; Linington et al., 1992; Schluesener et al., 1987) ."}

{"project":"CORD-19-PD-HP","denotations":[{"id":"T80","span":{"begin":166,"end":179},"obj":"Phenotype"}],"attributes":[{"id":"A80","pred":"hp_id","subj":"T80","obj":"http://purl.obolibrary.org/obo/HP_0011096"}],"text":"When antibodies to myelin oligodendrocyte glycoprotein (MOG) are injected after the induction of EAE, the severity of the disease is dramatically increased and large demyelinating lesions develop (Genain et al., 1995; Linington et al., 1992; Schluesener et al., 1987) ."}

{"project":"CORD-19-PD-UBERON","denotations":[{"id":"T93","span":{"begin":19,"end":25},"obj":"Body_part"}],"attributes":[{"id":"A93","pred":"uberon_id","subj":"T93","obj":"http://purl.obolibrary.org/obo/UBERON_0000345"}],"text":"When antibodies to myelin oligodendrocyte glycoprotein (MOG) are injected after the induction of EAE, the severity of the disease is dramatically increased and large demyelinating lesions develop (Genain et al., 1995; Linington et al., 1992; Schluesener et al., 1987) ."}